Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1990-2-22
|
pubmed:abstractText |
Based on the results of a retrospective study, which found blood vessel invasion to be the most important prognostic factor in clinical stage I nonseminomatous testicular germ cell cancer (NSTGCC I), a prospective study was started in 1985 which assigned NSTGCC I patients without evidence of vascular invasion to surveillance and patients with vascular invasion to two cycles of adjuvant chemotherapy with cisplatin, etoposide, and bleomycin. Twenty-two patients entered the surveillance group and 18 patients received adjuvant chemotherapy. Median follow-up is 30 months (3 to 50 months). Relapses occurred in three patients (7.5%), one in the surveillance group (4.5%), two in the chemotherapy group (11%). Thirty-eight patients (95%) are alive and without evidence of disease. Two patients of the adjuvant-treated group died, one of progressive germ cell cancer and one of lung cancer. We conclude that low- and high-risk NSTGCC I patients can be identified by considering blood vessel invasion. The presence of embryonal carcinoma and vascular invasion seem to be interrelated prognostic factors, because in 94% of vessel invasion the invading element was embryonal carcinoma. The exclusion of patients with vascular invasion from surveillance decreases relapse rates remarkably. Adjuvant chemotherapy diminishes relapse rates in high-risk patients but does not entirely prevent relapse.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0732-183X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
16-20
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1688613-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1688613-Bleomycin,
pubmed-meshheading:1688613-Cisplatin,
pubmed-meshheading:1688613-Etoposide,
pubmed-meshheading:1688613-Follow-Up Studies,
pubmed-meshheading:1688613-Humans,
pubmed-meshheading:1688613-Male,
pubmed-meshheading:1688613-Neoplasm Invasiveness,
pubmed-meshheading:1688613-Neoplasm Recurrence, Local,
pubmed-meshheading:1688613-Neoplasm Staging,
pubmed-meshheading:1688613-Neoplasms, Germ Cell and Embryonal,
pubmed-meshheading:1688613-Prognosis,
pubmed-meshheading:1688613-Prospective Studies,
pubmed-meshheading:1688613-Risk Factors,
pubmed-meshheading:1688613-Testicular Neoplasms
|
pubmed:year |
1990
|
pubmed:articleTitle |
Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial.
|
pubmed:affiliation |
Third Department of Medicine, Franz Josef Spital, Vienna, Austria.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|